Şunu aradınız:: standard symptom score (İngilizce - Maltaca)

change in composite investigator-assessed symptom score at 2 hours
bidla fl-iskor kompost tas- sintomi vvalutati mill- investigatur wara sagħtejn

the global symptom score also improved more in the patients taking prometax.
il-punteġġ globali tas-sintomi wkoll tjieb iktar fil-pazjenti ttrattati bi prometax.

the global symptom score also improved more in the patients taking rivastigmine hexal.
il-punteġġ globali tas-sintomi wkoll tjieb iktar fil-pazjenti ttrattati b'rivastigmine hexal.

the improvements in total international prostate symptom score occurred as early as 1 week.
it-titjib fit-total tal-punteġġ internazzjonali għas-sintomi tal-prostata deher kmieni mill-1 ġimgħa.

the global symptom score also improved more in the patients taking rivastigmine 1 a pharma.
il-punteġġ globali tas-sintomi wkoll tjieb iktar fil-pazjenti ttrattati b’rivastigmine 1 a pharma.

the study evaluated the mean symptom score using the change from baseline to the end of treatment.
l-istudju evalwa l- medja tal-punteġġ tas-sintomi bl-użu tal-bidla mil-linja bażi sat-tmiem tal-kura.

complete symptomatic response is defined as a 100% reduction in the baseline mcd overall symptom score sustained for at least 18 weeks prior to treatment failure
rispons sħiħ għas-sintomi huwa ddefinit bħala tnaqqis ta’ 100% fil-punteġġ globali tas-sintomi fil-linja bażi ta’ mcd li nżamm għal mill-anqas 18-il ġimgħa qabel falliet il-kura

symptom burden was assessed using the mpn-saf total symptom score (tss) electronic patient diary, which consisted of 14 questions.
il-piż tas-sintomi kien evalwat permezz tad-djarju elettroniku tal-pazjenti bi skor sintomatiku totali (tss) tal-mpn-saf, li kien jikkonsisti f’14-il mistoqsija.

table 3: mean symptom scores in adults (age 18 and older)
tabella 3: medja tal-punteġġi tas-sintomi fl-adulti (ta’ 18-il sena jew aktar)

improvement in key symptom scores was noted within one day of initiation of rilonacept therapy in most patients.
kien osservat titjib fil-punteġġi ewlenin tas-sintomi fi żmien jum mill-bidu tat-terapija b’rilonacept fil- biċċa l-kbira tal-pazjenti.

complete symptom response was defined as a 100% reduction from the baseline overall in the mcd-related overall symptom score sustained for at least 18 weeks prior to treatment failure.
rispons sħiħ għas-sintomi kien iddefinit bħala tnaqqis ta’ 100% mill-linja bażi totali fil-punteġġ ta’ sintomi totali marbuta ma’ mcd li jservi għal mill-inqas 18-il ġimgħa qabel ma l-kura ma tibqax taħdem aktar.

in part b, mean symptom scores increased more in patients withdrawn to placebo compared to patients who remained on rilonacept.
f’parti b, il-medja tal-punteġġ tas-sintomi żdiedet iktar f’pazjenti li kienu fuq il-plaċebo meta mqabbla ma’ pazjenti li baqgħu fuq rilonacept.

in both studies the main measure of effectiveness was the number of patients who responded to treatment after 24 weeks as shown by an improvement in symptom scores.
fiż-żewġ studji l- kejl ewlieni tal-effikaċja kien l-għadd ta’ pazjenti li kellhom rispons għall-kura wara 24 ġimgħa kif muri minn titjib fil-punteġġ tas-sintomi.

in the two studies in urticaria, the decrease in symptom score after six weeks of treatment with aerius was 58 and 67%, compared with 40 and 33% in placebo-treated patients.
fiż- żewġ studji dwar l- urtikarja, wara trattament ta 'sitt ġimgħat b' aerius, it- tnaqqis fil- punteġġ tas- sintomi kien 58 u 67%, meta mqabbel ma' 40 u 33% f' pazjenti li kienu qed jieħdu plaċebo.

the children received placebo or stelara and the main measure of effectiveness was the number of patients who responded to treatment after 12 weeks as shown by an improvement in symptom scores.
it-tfal ingħataw plaċebo jew stelara u l-kejl ewlieni tal-effikaċja kien l-għadd ta’ pazjenti li kellhom rispons għall-kura wara 12-il ġimgħa kif muri minn titjib fil-punteġġ tas-sintomi.

patients treated with rilonacept experienced an 84% reduction in the mean symptom score in part a compared to 13% for placebo-treated patients (p< 0.0001).
pazjenti kkurati b’rilonacept kellhom tnaqqis ta’ 84% fil-medja tal-punteġġ tas-sintomi f’parti a meta mqabbel ma’ 13% għal pazjenti kkurati bil-plaċebo (p< 0.0001).

during the open-label extension, reductions in mean symptom scores, serum crp, and serum saa levels were maintained for up to one year.
matul l-estensjoni tat-tip open label, it-tnaqqis fil-medja tal-punteġġi tas-sintomi, fil-livelli ta’ crp tas-serum, u ta’ saa tas-serum, inżamm sa sena.

symptom scores were around 100 points at the start of the study, but had fallen by around 25 points in the patients receiving zypadhera after eight weeks, compared with around 9 points in the patients receiving placebo.
il- punteġġi relatati mas-sintomi kienu madwar 100 punt fil-bidu tal-istudju iżda fil-pazjenti ttrattati b’zypadhera kienu naqsu b’madwar 25 punt wara tmien ġimgħat, meta mqabbla ma’ madwar 9 punti fil-pazjenti ttrattati bil-plaċebo.

in the first short-term study, patients taking placebo had an average fall in their symptom score of 4.1 points, compared with an average fall of between 17.9 and 23.3 points in those taking invega and of 19.9 in those taking olanzapine.
fl- ewwel studju li ħares lejn l- effetti fil- futur qrib, il- pazjenti li kienu qed jieħdu l - plaċebo kellhom medja ta 'tnaqqis fil- punteġġ tas- sintomi ta' 4. 1 punti, meta mqabbla ma 'tnaqqis medju ta' bejn 17. 9 u 23. 3 punti f' dawk il- pazjenti li kienu qed jieħdu invega u ta '19. 9 f' dawk li kienu qed jieħdu olanzapine.

the main measure of effectiveness was the proportion of patients who ‘responded’ to treatment after 12 weeks, meaning that symptom scores improved by 75% or more.
il-miżura ewlenija ta’ l- effettività kienet il-proporzjon ta’ pazjenti li ‘irrispondew’ għal kura wara 12-il ġimgħa, li tfisser li l- iskors tas-sintomi tjiebu b’75% jew aktar.